MA43828B1 - Agents thérapeutiques pour maladies neurodégénératives - Google Patents

Agents thérapeutiques pour maladies neurodégénératives

Info

Publication number
MA43828B1
MA43828B1 MA43828A MA43828A MA43828B1 MA 43828 B1 MA43828 B1 MA 43828B1 MA 43828 A MA43828 A MA 43828A MA 43828 A MA43828 A MA 43828A MA 43828 B1 MA43828 B1 MA 43828B1
Authority
MA
Morocco
Prior art keywords
neurodegenerative diseases
therapeutic agents
leucine
acetyl
administration
Prior art date
Application number
MA43828A
Other languages
English (en)
French (fr)
Other versions
MA43828A (fr
Inventor
Michael Strupp
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59859424&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA43828(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1613829.9A external-priority patent/GB201613829D0/en
Priority claimed from GBGB1702551.1A external-priority patent/GB201702551D0/en
Priority claimed from GBGB1705766.2A external-priority patent/GB201705766D0/en
Priority claimed from GBGB1706867.7A external-priority patent/GB201706867D0/en
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of MA43828A publication Critical patent/MA43828A/fr
Publication of MA43828B1 publication Critical patent/MA43828B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA43828A 2016-08-11 2017-08-11 Agents thérapeutiques pour maladies neurodégénératives MA43828B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1613829.9A GB201613829D0 (en) 2016-08-11 2016-08-11 Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage
GBGB1702551.1A GB201702551D0 (en) 2017-02-16 2017-02-16 Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage
GBGB1705766.2A GB201705766D0 (en) 2017-04-10 2017-04-10 Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage
GBGB1706867.7A GB201706867D0 (en) 2017-04-28 2017-04-28 Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage
PCT/IB2017/054929 WO2018029658A1 (en) 2016-08-11 2017-08-11 Therapeutic agents for neurodegenerative diseases

Publications (2)

Publication Number Publication Date
MA43828A MA43828A (fr) 2018-12-26
MA43828B1 true MA43828B1 (fr) 2019-09-30

Family

ID=59859424

Family Applications (2)

Application Number Title Priority Date Filing Date
MA43828A MA43828B1 (fr) 2016-08-11 2017-08-11 Agents thérapeutiques pour maladies neurodégénératives
MA047521A MA47521A (fr) 2016-08-11 2017-08-11 Agents thérapeutiques pour maladies neurodégénératives

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA047521A MA47521A (fr) 2016-08-11 2017-08-11 Agents thérapeutiques pour maladies neurodégénératives

Country Status (28)

Country Link
US (3) US12144792B2 (enExample)
EP (3) EP4467195A3 (enExample)
JP (3) JP6957602B2 (enExample)
KR (4) KR20220093385A (enExample)
CN (4) CN116492328A (enExample)
AU (3) AU2017308865B2 (enExample)
BR (1) BR112019002730A2 (enExample)
CA (1) CA3033564A1 (enExample)
CY (1) CY1121930T1 (enExample)
DK (1) DK3416631T3 (enExample)
ES (1) ES2733677T3 (enExample)
HR (1) HRP20191055T1 (enExample)
HU (1) HUE045043T2 (enExample)
IL (3) IL310799A (enExample)
LT (1) LT3416631T (enExample)
MA (2) MA43828B1 (enExample)
MD (1) MD3416631T2 (enExample)
ME (1) ME03454B (enExample)
MX (3) MX383499B (enExample)
PL (1) PL3416631T3 (enExample)
PT (1) PT3416631T (enExample)
RS (1) RS59048B1 (enExample)
RU (1) RU2756519C2 (enExample)
SG (1) SG11201901063SA (enExample)
SI (1) SI3416631T1 (enExample)
SM (1) SMT201900370T1 (enExample)
TN (1) TN2019000033A1 (enExample)
WO (1) WO2018029658A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10219815B2 (en) 2005-09-22 2019-03-05 The Regents Of The University Of Michigan Histotripsy for thrombolysis
CN108348772B (zh) 2015-06-24 2020-03-03 美国密歇根州立大学试剂中心 用于治疗脑组织的组织摧毁术治疗系统和方法
MA43876B1 (fr) * 2016-08-11 2019-04-30 Intrabio Ltd Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale
AU2017308865B2 (en) 2016-08-11 2023-04-13 Intrabio Limited Therapeutic agents for neurodegenerative diseases
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
RU2763425C2 (ru) * 2017-10-18 2021-12-29 Интрабио Лимитед Терапевтические агенты для нейродегенеративных заболеваний
AU2019221886B2 (en) 2018-02-15 2024-08-08 Intrabio Ltd Therapeutic agents for treating restless legs syndrome
EP3886737A4 (en) 2018-11-28 2022-08-24 Histosonics, Inc. HISTOTRIPSY SYSTEMS AND METHODS
JP7471298B2 (ja) * 2018-12-06 2024-04-19 イントラビオ エルティーディー アセチル－ロイシンの重水素化類似体
SI3934637T1 (sl) * 2019-03-02 2024-10-30 Intrabio Ltd Summit House (N-)acetil-L-levcin za uporabo pri zdravljenju travmatske poškodbe možganov
EP4030993A4 (en) * 2019-09-17 2023-10-25 F. Hoffmann-La Roche AG Improvements in personalized healthcare for patients with movement disorders
US20230051742A1 (en) * 2020-01-13 2023-02-16 Intrabio Ltd. Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers
WO2022264037A1 (en) * 2021-06-14 2022-12-22 Intrabio Ltd. Branched-chain amino acid derivatives to treat disease
AU2023366591A1 (en) 2022-10-28 2025-04-24 Histosonics, Inc. Histotripsy systems and methods
AU2024257180A1 (en) 2023-04-20 2025-09-18 Histosonics, Inc. Histotripsy systems and associated methods including user interfaces and workflows for treatment planning and therapy
WO2025151578A1 (en) * 2024-01-12 2025-07-17 Intrabio Inc. N-acetyl-leucine for use in the treatment of prodromal alpha-synucleinopathies
WO2025163129A1 (en) * 2024-02-01 2025-08-07 Intrabio Ltd. Acetyl-leucine for treating parkinson´s disease
US12403111B2 (en) 2024-02-02 2025-09-02 SynGAP Research Fund Compositions and methods for treating neurodevelopmental disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060063827A1 (en) 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
US20050222209A1 (en) * 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
FR2905600B1 (fr) * 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
WO2008101692A2 (en) 2007-02-22 2008-08-28 Beiersdorf Ag Cosmetic and pharmaceutical applications of n-acetylhydroxyproline
TN2010000251A1 (fr) 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
TN2010000566A1 (en) 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
SG10201810496XA (en) * 2013-10-28 2018-12-28 Naurex Inc Nmda receptor modulators and prodrugs, salts, and uses thereof
KR102791288B1 (ko) 2016-04-19 2025-04-03 인트라바이오 리미티드 이동성 및 인지 기능을 개선시키기 위한 아세틸-류신 또는 이의 약제학적으로 허용되는 염
AU2017308865B2 (en) 2016-08-11 2023-04-13 Intrabio Limited Therapeutic agents for neurodegenerative diseases

Also Published As

Publication number Publication date
PT3416631T (pt) 2019-07-11
KR102785448B1 (ko) 2025-03-21
SI3416631T1 (sl) 2019-09-30
RU2019106506A (ru) 2020-09-17
MA43828A (fr) 2018-12-26
SG11201901063SA (en) 2019-03-28
KR20220093385A (ko) 2022-07-05
MX2024004439A (es) 2025-11-03
CN121081445A (zh) 2025-12-09
IL264641A (en) 2019-04-30
SMT201900370T1 (it) 2019-09-09
LT3416631T (lt) 2019-08-26
RU2019106506A3 (enExample) 2020-10-29
US20240189267A1 (en) 2024-06-13
IL310801A (en) 2024-04-01
RS59048B1 (sr) 2019-08-30
EP4467195A2 (en) 2024-11-27
US20230210799A1 (en) 2023-07-06
EP3416631A1 (en) 2018-12-26
JP2022003085A (ja) 2022-01-11
AU2023202121B2 (en) 2025-01-23
MD3416631T2 (ro) 2019-09-30
JP2019524822A (ja) 2019-09-05
JP2023175762A (ja) 2023-12-12
ES2733677T3 (es) 2019-12-02
HUE045043T2 (hu) 2019-12-30
KR20190039227A (ko) 2019-04-10
RU2021128045A (ru) 2021-11-16
DK3416631T3 (da) 2019-07-15
EP4467195A3 (en) 2025-03-19
CN116492328A (zh) 2023-07-28
EP3583940A1 (en) 2019-12-25
US12144792B2 (en) 2024-11-19
IL264641B2 (en) 2024-07-01
KR20240068761A (ko) 2024-05-17
AU2017308865B2 (en) 2023-04-13
PL3416631T3 (pl) 2019-11-29
RU2756519C2 (ru) 2021-10-01
IL310799A (en) 2024-04-01
EP3416631B1 (en) 2019-05-15
MA47521A (fr) 2021-04-21
TN2019000033A1 (fr) 2020-07-15
AU2023202121A1 (en) 2023-05-04
AU2017308865A1 (en) 2019-02-21
MX2019001575A (es) 2019-08-01
BR112019002730A2 (pt) 2019-05-14
JP6957602B2 (ja) 2021-11-02
CA3033564A1 (en) 2018-02-15
KR102413756B1 (ko) 2022-06-27
MX383499B (es) 2025-03-14
HRP20191055T1 (hr) 2019-09-06
WO2018029658A1 (en) 2018-02-15
ME03454B (me) 2020-01-20
US20200179320A1 (en) 2020-06-11
KR20250042197A (ko) 2025-03-26
CN109789114A (zh) 2019-05-21
MX2021006901A (es) 2021-07-07
AU2025202077A1 (en) 2025-04-10
CY1121930T1 (el) 2020-10-14
IL264641B1 (en) 2024-03-01
CN116459244A (zh) 2023-07-21

Similar Documents

Publication Publication Date Title
MA43828A (fr) Agents thérapeutiques pour maladies neurodégénératives
MA49664A (fr) Combinaisons d'un dérivé de 4-pyrimidinesulfamide avec des principes actifs pour le traitement de maladies liées à l'endothéline
EP3490987A4 (en) INNOVATIVE THERAPEUTIC AGENTS FOR THE TREATMENT OF HBV INFECTION
MA49279A (fr) Compositions d'anticorps optimisées pour le traitement de troubles oculaires
EP3829569A4 (en) SPINOSYN FORMULATIONS FOR THE TREATMENT OF DEMODEX-INDUCED EYE AND FACIAL DISORDERS
MA40755B1 (fr) Compositions comprenant des souches bactériennes
MA40754B1 (fr) Compositions comprenant des souches bactériennes
EA201992607A1 (ru) Твердые формы берберина урсодезоксихолата, их композиции и способы
EP3607952A4 (en) USE OF CARRIMYCIN AND PHARMACEUTICAL ACCEPTABLE SALT THEREOF FOR THE PRODUCTION OF A MEDICINAL PRODUCT FOR THE TREATMENT AND PREVENTION OF TUMORS
EP3481385C0 (en) Pulsatile drug delivery system for the treatment of morning akinesia
MA54077A (fr) Polythérapie pour le traitement de maladies hématologiques
EP3539550A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASES WITH FLOWER EXTRACT OF LILAC SOIL BAST OR FRACTIONS THEREOF AS AN ACTIVE SUBSTANCE
MA51136A (fr) Traitement des maladies monogéniques à l'aide d'un anticorps anti-cd45rc
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
MA43876B1 (fr) Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MA39837B1 (fr) Quinazoline-thf-amines halogénées en tant qu'inhibiteurs de la pde1
MX2020003427A (es) Agentes terapeuticos para enfermedades neurodegenerativas.
EP3530278A4 (en) COMPOSITION WITH PROTEIN-PHOSPHATASE-1-INHIBITING PEPTIDE FOR THE TREATMENT OF VASCULAR DISEASES
MA44660B1 (fr) (+) -azasetron pour son utilisation dans le traitement des troubles de l'oreille
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MA46778A1 (fr) Composition intranasale comprenant de la bétahistine
MA39533A1 (fr) Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives
MA41975B1 (fr) Derives d'aminohydrothiazine fusionnee contenant du tetrahydrofurane utiles dans le traitement de la maladie d'alzheimer
MX2021014093A (es) Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson.